News

Using a combination of two standardized assessment tools may be better than the classification process now in place in predicting the outcomes of people with a thymoma, or thymus tumor, associated with myasthenia gravis (MG), a new study suggests. The newly proposed system, from researchers in China, would classify…

The first patient has been dosed in a Phase 3 clinical trial that’s assessing the safety and efficacy of oral cladribine for treating generalized myasthenia gravis (gMG). The study, called MyClad (NCT06463587), is intended to test whether short courses of cladribine treatment can outperform a placebo at easing…

Mycophenolate mofetil (MMF) safely and effectively controlled symptoms of generalized myasthenia gravis (gMG) in patients switching from azathioprine, another immunosuppressive agent, a study finds. “This study supports the efficacy and safety of MMF in the treatment of MG,” wrote the study’s researchers, who said more research with a…

Combining Vyvgart (efgartigimod) with steroid therapy resolved a myasthenic crisis, a potentially life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems, in a 70-year-old Japanese woman with generalized MG (gMG), a case study shows. The combined therapy successfully treated the myasthenic crisis in the absence…

Johnson & Johnson has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of nipocalimab to treat people with generalized myasthenia gravis (gMG). The application covers gMG patients who are positive for disease-causing antibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), and low…

Serious breathing difficulties, called acute respiratory distress, was the initial clinical manifestation of myasthenia gravis (MG) in a 41-year-old woman, who was described in a recent case study. The woman went to the emergency room with severe breathing problems, progressive shortness of breath, coughing, and difficulty swallowing. She was…

Taking Rituximab by itself is as effective as combining it with corticosteroids for treating myasthenia gravis (MG) and has the benefit of reducing the proportion of patients who need rescue therapy and use immunosuppressants, a French study finds. According to researchers, “this indicates that avoiding steroids could reduce…

More than half of myasthenia gravis (MG) patients have fatigue, the severity of which is strongly correlated with their history of exacerbations, that is episodes when their disease worsens, and/or crises, along with delays in their diagnosis. That’s according to a nationwide registry study in Germany that found…

The volume of the extraocular muscles controlling eye movements is decreased in Chinese patients with myasthenia gravis (MG), particularly in those with ophthalmoparesis, or limited eye movement, a study found. Long disease duration was also associated with decreased extraocular muscle volume, but only in patients with ophthalmoparesis. A reduction…

Rituximab effectively treated most myasthenia gravis (MG) patients who were positive for antibodies against muscle-specific tyrosine kinase (MuSK), a small study shows. The therapy eased MG symptoms and led to gains in measures of clinical severity. It also enabled patients to reduce or stop taking other medications,…